

06-04-07

1634
15W

Attorney Docket No. 5470-401

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re: Stafford et al.

Confirmation No.: 4529

Application No.: 10/573,131

Group Art Unit: 1634

Filed: April 18, 2006

Examiner: J. Sitton

For: *METHODS AND COMPOSITIONS FOR THE CORRELATION OF SINGLE
NUCLEOTIDE POLYMORPHISMS IN THE VITAMIN K EPOXIDE
REDUCTASE GENE AND WARFARIN DOSAGE*

Date: June 1, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)**

Sir:

Attached is a list of documents, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401
Customer No. 20792

Respectfully submitted,


Mary L. Miller
Mary L. Miller
Registration No. 39,303

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

"Express Mail" mailing label number: EV 854928665 US ; Date of Deposit: June 1, 2007

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Evelyn Casey
Evelyn Casey

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
		Application Number		10/573,131	
		Filing Date		April 18, 2006	
		First Named Inventor		Darrel W. Stafford	
		Group Art Unit		1634	
		Examiner Name		J. Sitton	
Attorney Docket Number		5470-401			
Sheet	1 of 1				

U.S. PATENTS AND PATENT PUBLICATIONS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation
		Office	Number	Kind Code (if known)			
							No

OTHER NON PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	1.	ICOS "Factor IX Cell Culture Process" Version 2.0 (12 pages) (2006)	
	2.	Bogousslavsky et al. "Anticoagulant-induced intracerebral bleeding in brain ischemia" <i>Acta Neurol Scand.</i> 71:464-471 (1985)	
	3.	Chen et al. "Calcium Phosphate-Mediated Gene Transfer: A Highly Efficient Transfection System for Stably Transforming Cells with Plasmid DNA" <i>BioTechniques</i> 6(7):632-638 (1988)	
	4.	Ekelund et al. "Combined Deficiency of Coagulation Factors II, VII, IX, and X: A Case of Probable Congenital Origin" <i>Pediatric Hematology and Oncology</i> 3:187-193 (1986)	
	5.	Furuya et al. "Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy" <i>Pharmacogenetics</i> 5:389-392 (1995)	
	6.	Gan et al. "Racial Background Is a Determinant Factor in the Maintenance Dosage of Warfarin" <i>International Journal of Hematology</i> 78:84-86 (2003)	
	7.	Gullov et al. "Bleeding Complications to Long-Term Oral Anticoagulant Therapy" <i>Journal of Thrombosis and Thrombolysis</i> 1:17-25 (1994)	
	8.	Nasu et al. "Genetic analysis of CYP2C9 polymorphism in a Japanese population" <i>Pharmacogenetics</i> 7:405-409 (1997)	
	9.	Prentice "Acquired Coagulation Disorders" <i>Clin. Haematol.</i> 14(2):413-442 (1985)	
	10.	Suttie "The Biochemical Basis of Warfarin Therapy" <i>Adv. Exp. Med. Bio.</i> 214:3-16 (1987)	
	11.	Vermeer et al. "Vitamin K-Dependent Carboxylase" <i>Haematologia</i> 18(2):71-97 (1985)	
	12.	Vincente et al. "Congenital Deficiency of Vitamin K-Dependent Coagulation Factors and Protein C" <i>Thromb Haemostas (Stuttgart)</i> 51(3):343-346 (1984)	
	13.	Wallace et al. "A major gene controlling warfarin-resistance in the house mouse" <i>J. Hyg., Camb.</i> 76:173-181 (1976)	
	14.	Yu et al. "Factors determining the maintenance dose of warfarin in Chinese patients" <i>Q J Med</i> 89:127-135 (1996)	
	15.	Zwaal et al. "Lipid-protein interactions in blood coagulation" <i>Biochimica et Biophysica Acta</i> 1376:433-453 (1998)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.